Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized
  • Cyclosporine / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Methotrexate
  • Pharmaceutical Preparations*
  • Registries

Substances

  • Antibodies, Monoclonal, Humanized
  • Pharmaceutical Preparations
  • dupilumab
  • Cyclosporine
  • Methotrexate